Login to Your Account



Shire sees HAE attack reductions in phase III of '616

By Michael Fitzhugh
Staff Writer

Monday, September 11, 2017

Shire plc reported that SHP-616, a ready-to-use subcutaneous formulation of its C1 esterase inhibitor, Cinryze, significantly reduced HAE attacks vs. placebo in a phase III study that laid the groundwork for the company to seek regulatory approvals of the candidate.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription